protein phosphatase 1 regulatory subunit 3EGenealiases: []
Q-omics provides the consensus-scored PPP1R3E profile across patient tissues and cancer cell-line models. PPP1R3E expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PPP1R3E is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, PPP1R3E RNA expression shows 19,928 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and LIHC as cancer lineages where PPP1R3E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPP1R3E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPP1R3E survival associations across molecular data types. PPP1R3E RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPP1R3E RNA expression–survival associations across cancer types. High PPP1R3E expression shows unfavorable associations in UVM, but favorable associations in HNSC, SKCM, BRCA, PAAD and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PPP1R3E RNA expression.
This table summarizes PPP1R3E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PPP1R3E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPP1R3E shows lower tumor expression in THCA, BRCA, KIRC, UCEC and BLCA and higher tumor expression in LIHC. The LIHC box plot shows higher PPP1R3E RNA expression in tumor versus normal tissue (log2 FC = +0.914, t-test p < 0.001).
This table shows molecular features associated with PPP1R3E in patient tissues and cancer cell lines. In patient samples, PPP1R3E shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PPP1R3E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
